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Rearrangement  and  Reverse  Transcriptase-Polymerase  Chain  Reaction 
for t(4; ll)(q21;  q23) 
By Joanne M. Hilden, Joy L. Frestedt, Roderick 0. Moore, Nyla A. Heerema, Diane C.  Arthur, 
Gregory H.  Reaman, and John H. Kersey 
Molecular  techniques  to detect MLL (llq23)  and AF-4 (4q21) 
gene  rearrangements  are  being  evaluated  for  use  in stratifi- 
cation of  patients into prognostic  groups.  We studied 15 
cases  of  infant acute  lymphoblastic  leukemia  (ALL)  with 
Southern blotting for MLL gene rearrangement  and  reverse 
transcriptase-polymerase  chain  reaction  (RT-PCR)  for  t(4; 11) 
fusion  transcripts  and  compared  the  results to  cytoge- 
netic and  clinical  data.  Our  results  indicate  that  classic 
t(4;11)(q21;q23)  translocations  are  detected  by  RT-PCR; 
however,  unusual  4; 11 translocations still require  additional 
NFANT ACUTE lymphoblastic leukemia (ALL), because 
of  its poor  response to therapy, has  been  extensively 
studied to define prognostic indicators. Disease characteris- 
tics associated with poor outcome are age less than 6 months, 
white blood cell (WBC) count greater than SO,OOO/pL, and 
CDIO-  phen~type.“~  Infant ALL has  a high  incidence of 
cytogenetic 1 lq23 rearrangements (43% to 60%),5-8  with the 
t(4; 1  l)(q21;q23)  being  the  most  common  translocation 
among many different 1  lq23 translocation partners.’”’  Stud- 
ies using Southern analysis of the MLL (mixed-lineage leu- 
kemia) gene at chromosome band  llq23 consistently show 
that infant ALL with rearrangement of this gene has a dismal 
progn~sis.””~  However, the survival of infants without this 
rearrangement has been less consistent, from 50%” to 67%12 
to the 80% reported by  Chen  et al.’4  Current debate centers 
around which patients will need intensified therapy. For this 
reason we have added to and updated the group of infants 
originally reported by Chen et all4; the infants with germline 
MLL configuration continue to do very  well. 
Among MLL-rearranged patients, cytogenetic data sug- 
gest that it is the t(4; 11) that confers a poor progno~is’~’~~~~.~~ 
and that infants with 1  lq23 translocation partners other than 
the  AF-4 gene at chromosome band 4q21 do somewhat bet- 
ter, but the number of  such cases is sma1L8 The prognostic 
significance of  specific llq23 translocations may  become 
more clear with the use of  molecular techniques to  detect 
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investigation.  We  also  extended and updated our  original 
study of  MLL gene rearrangement in infant ALL  to 40 pa- 
tients with longer follow-up and  show that  the group with 
germline  configuration of the MLL  gene  continues to have 
an  excellent  outcome.  The results of  salvage therapy (bone 
marrow  transplantation or  chemotherapy)  suggest  that 
transplant may show  an  advantage.  Preliminary  results  of 
the use  of  RT-PCR  to assess minimal disease  are  also re- 
ported. 
0  1995 by The American  Society of Hematology. 
these  translocations in  cases  with  inadequate cytogenetic 
data. Reverse transcriptase-polymerase chain reaction (RT- 
PCR) has been  used  to  detect fusion transcripts resulting 
from specific translocations; however, this technique relies 
on known sequence data to design PCR primers around clas- 
sic translocation breakpoints. We and others have reported 
an RT-PCR assay for t(4; 11) fusion  transcript^.'"^^ We re- 
port here 15 cases of  infant ALL examined with  both South- 
ern analysis of  the MLL gene and RT-PCR for MLWAF-4 
fusion transcripts. Those with nonclassic cytogenetic t(4; 11) 
breakpoints show that MLL rearrangement (reliably detected 
by  Southern blot) does not  always lead to  standard fusion 
transcripts detectable by PCR. This finding has implications 
as to which molecular tests are used to determine prognostic 
groups. 
Intensification of therapy involves chemotherapy or bone 
marrow transplantation (BMT); there are few data available 
as to their efficacy in salvage therapy. The patients in our 
study whose disease relapsed were salvaged either with BMT 
or chemotherapy; the outcome for these infants is reported. 
In addition, we report preliminary results of a study assessing 
minimal residual disease (MRD) in t(4; 11) acute leukemia 
using RT-PCR. 
MATERIALS AND  METHODS 
Patients and  specimens.  Bone marrow (BM)  or peripheral blood 
(PB) samples were obtained from 15 infants (5  12 months of age) 
with newly diagnosed ALL  who  were enrolled and treated on Chil- 
drens Cancer Group (CCG) 1883, the most recently completed CCG 
infant ALL protocol. Treatment includes induction with vincristine, 
prednisone, L-Asparaginase, and daunomycin (VPLD) and intrathe- 
cal methotrexate and postinduction therapy with rotating combina- 
tions of  high-dose Ara-C, very high dose methotrexate with citrov- 
orum factor rescue, VPLD, 6MP, and cytoxan. Cases were selected 
only on the basis of  availability of cryopreserved blasts. These  15 
cases were studied both  by  RT-PCR for MLUAF-4 fusion transcripts 
and by  Southem analysis for MLL gene rearrangement. The results 
of  Southern analysis have been previously reported for 6 of these 
infants in a study of  the impact of MLL gene rearrangement on  the 
outcome of  30 infants treated for ALL on 3 CCG pro to col^.'^  In 
total, 40 (CCG 191,*’  2 patients; CCG 107,3 14 patients; and CCG 
1883, 24 patients) infants have now  been studied for MLL gene 
rearrangement, and their outcome has been updated for this report, 
including the results of  salvage therapy. 
In addition, 4 other t(4; 1 1) ALL patients, who were 4 months to 
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20  years  of  age  at  diagnosis,  were  studied  at  various  timepoints  on 
therapy  for the  presence  of  MLL/AF-4  fusion  transcripts  by  RT- 
PCR. PB  or BM or postmortem  spleen or liver  specimens  (homoge- 
nized  with  a Dounce  homogenizer)  were  studied.  RNA and  DNA 
were  prepared  as  described."  MLWAF-4-positive  (RS41Iz2  and 
BIz3)  and  -negative  (Nalm-6)24  cell  lines  have been  previously  de- 
scribed. 
fmmunuphenotyping.  The  immunophenotyping  was  performed 
in  CCG  reference  laboratories  at  Children's  National  Medical  Center 
(Washington,  DC)  or the  University  of  Minnesota  (Minneapolis, 
MN).  Cell-surface  antigens  were  considered  positive  if  they  were 
expressed on  20%  or  more of  the  cells. 
Cyrogenetics.  Cytogenetic  analysis  was  performed  at  local 
CCG-affiliated  institutions.  Karyotypes  were  subsequently  centrally 
reviewed;  to  include a normal  case  as  adequate,  analysis of  at  least 
20  metaphases  was  required.  All  cases  were  banded,  with  a minimum 
band  level  of  400. 
Sfafistical analysis.  Life  table  comparisons  were  made  for  the 
groups  with  and  without  MLL  gene  rearrangement  using  the  Mantel- 
Peto-Cox  summary  The  endpoint  used  in  the  life  table  analysis 
was event-free  survival  (EFS); an  event  was  defined  as  occurrence 
of  any  relapse  or death  after  first  remission. 
RT-PCR for  the  MWAF-4 fusion  transcript.  Polyadenylated 
RNA was extracted  and  cDNA  synthesized  as previously  described." 
The  PCR  primers  (M1 in  MLL  exon  6, and AI and A2  in  AF-4) 
that  amplify  the  derivative  11 fusion  transcript  resulting  from  the 
t(4; 11) translocation  have  been  previously  reported."  In  addition, 
we  have  used  two  nested  primers,  M5b  (AAGTGGCTCCCCGCC- 
CAAGTAT)  in  MLL  exon  5 and  A43b  (ITGGGTTACAGAACT- 
GACATG)  in  AF-4.  The  location  of  the  AF-4  primers  is such  that 
classic  AF-4  breakpoints  as  well  as  breakpoints  up  to  400  bp  down- 
stream  from  the  cluster  region  would  be detected.  Amplification  was 
performed  with  Taq polymerase  as  previously  rep~rted.'~ 
Any initially  negative  RT-PCR  reactions  with  the  first  set  of  prim- 
ers  were  repeated  using  the  nested  primers  with 5% of the original 
PCR product.  Amplification  of P-actin RNA  was  performed  to  dem- 
onstrate  integrity of  isolated RNA. Strict  precautions  were  used  to 
prevent  contamination  of  samples,  and  positive  and  negative  controls 
were  included  at  all steps. PCR  products  were  separated  by  electro- 
phoresis  on  a 1% agarose  gel.  The DNA  was  transferred  to a nylon 
membrane  and  probed  with  y32P-labeled  oligonucleotides  specific 
for MLL (GAATCAGGTCCAGAGCAGA)  and  AF-4  (TGACCC- 
AlTCATGGCCTCCT). PCR  products  were  cloned  and  sequenced 
as previously  reported."  The  AF-4  exon  terminology  is as  described 
in  Downing  et a1.I8 
Defection  of MLL gene rearrangement by Southern analysis,  Ge- 
nomic  DNA  was  extracted,  digested  with  restriction  endonucleases 
(EcuRI, HindIII, and BamHI), and  analyzed by  Southern  blotting  as 
de~cribed.'~  The  probes  used  to  detect  rearrangement  of the  MLL 
gene at chromosome  band  llq23 have  been 
RESULTS 
RT-PCR for detection of  the t(4;  11) (MWAF-4)  fusion 
transcript.  We  tested  15 infants  with  ALL  for  MLL  gene 
rearrangements  and  MLL/AF-4  fusion  transcripts;  the  results 
are shown  in  Table  1. Three  patients  had  a germline  MLL 
gene configuration  (patients no.  1 through  3)  without  evi- 
dence of fusion transcripts by  RT-PCR.  Two  of these  patients 
had insufficient  metaphases  for  cytogenetic  testing,  and 1 
had a normal  male  karyotype.  Five  patients  (no.  4 through 
8) with  MLL  gene  rearrangement  by  Southern  analysis  were 
also negative  for  MLUAF-4  fusion  transcripts.  Of interest, 
2 of these  (patients  no.  6 and  7)  had  unusual  4; 1  l transloca- 
tions. Patient  no. 6 had  breakpoints  at $13  and  llq23,  and 
patient no. 7 had  breakpoints  at 4q35 and 1 lq14-q22 {very 
close  to  llq23).  There was insufficient  material  to test for 
t(l1;  19)  fusion  transcripts.  In-depth analysis of these  patients 
with  MLL  rearrangement  but  without detectable  MLUAF- 
4 fusion transcripts is needed to  determine  the  nature of the 
molecular  defect, 
One  patient  (no.  9)  had  unsuccessful  cytogenetics  and 
MLL  gene  rearrangement  by  Southern  analysis  and  a MLU 
AF-4  fusion transcript by  RT-PCR. This patient  had a very 
short first remission.  Patient  no.  10, who  had a classic cyto- 
genetic  derivative I1  chromosome but an unusual derivative 
4 chromosome,  showed a classic  MLUAF-4  fusion  by  RT- 
PCR.  The  remaining  5 patients  had  a classic t(4; 11)  with 
MLL  gene  rearrangement  and  the  MLL/AF-4  fusion  tran- 
script  by  PCR. 
Sequencing of the PCR products  identified  the MLL and 
AF-4  exons  involved  in  each  translocation  (Table 1). The 
sequences of three  patients  were  part  of our original report"; 
the 4 additional  patients  sequenced  showed  no  new  AF-4 
breakpoints.  All  patients  analyzed  so far  have  shown  MLL 
exons 6, 7, or 8 joined  to AF-4 exons a, b, or, rarefy, 
MLL gene rearrangement.  We  have  examined  40 cases 
of infant  ALL;  29  (72.5%)  show  rearrangement  of the  MLL 
gene  and  11 (27.5%) are not  rearranged  (Table  2). As ex- 
pected,  MLL  gene  rearrangement  correlated with a CD10-, 
CD19'  phenotype.  Three  of  29  rearranged  cases  were 
CD10+  and 1 of  26 tested was  CD19-.  Nine  of 11 germline 
cases  were  CD10+  and  1 of 9 tested was CD19-. Cytogenetic 
results  are  listed  in  abbreviated  form  in  Table  2.  All  8 
cases of cytogenetic 1  lq23  rearrangement  were  detected by 
Southern blotting  with  our MLL gene probes.  Nine of  17 
cases  with  unsuccessful  or  normal  cytogenetics  had  re- 
arrangements  in  MLL  detected by Southern blot. 
MLL gene  rearrangement  and  treatment  outcome.  Fig- 
ure 1 shows  the  disease-free survival  in  this group of  infants. 
The  patients  studied  did  not  differ from  the  group  without 
frozen  specimens  available  as  far  as  induction  rate,  WBC 
count  at  diagnosis,  and  overall  survival. The  absence  of MLL 
gene rearrangement,  now with  longer  follow-up  since  our 
original report,14 continues  to  identify a group of infants with 
a good prognosis. MLL  gene rearrangement  was associated 
with a  16-fold increased risk of  an  adverse  event.  The  pro- 
jected EFS at 24  months  was  28%  for  the rearranged group 
and  100%  for  the  nonrearranged  group.  Among the patients 
with  MLL  gene  rearrangement,  there  are  too  few  with  molec- 
ular data  showing  absence  of the  MLWAF-4  fusion  transcript 
to  determine whether  they  do  better  than  those  with  the 
classic t(4; 11). 
Among  the  group  of 11 infants with  germline  MLL  (the 
oldest patient being diagnosed in 1982),  there  has  been only 
one  relapse;  this patient  was  salvaged  with  chemotherapy 
and  is  alive  without disease  77  months  after  diagnosis. Cyto- 
genetic  analysis of this  group  has  not  identified other high- 
risk  translocations.  For  the  group  with  MLL  gene  re- 
arrangement,  only 2 of 29  did  not  achieve  remission  by  day 
28 (I of these did so by day 42); of the 28 ultimately  achiev- 
ing  remission,  21  have  relapsed. Five  patients  remain  in  first 
remission after treatment  with  chemotherapy  only; 2 patients 
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Table 1.  Results of  Cytogenetics, Southern Analysis of the  MLL Gene, and RT-PCR for the  MLL/AF4 Fusion Transcript in  Infant ALL 
Patient 
No. 
der11 Fusion Transcript:  Duration 
MLL  PCR  MLL ExonlAF-4 Exon  CR1 (mo)  Karyotype [no. of cells] 
1  Inadequate study  G  -  ND 
3  46,XYI201  -  ND 
4  46,XX1201  ND  29 + 
5  not available  R  -  ND 
7  49,XX.+X,+6,+10,t(4;ll)(q35;ql4-22~[231  R  -  ND  13 
9  Inadequate study  R  +  MLL6/AF-4a 
2  Inadequate study  G  -  ND 
50+ 
18+ 
35+  G 
R  - 
6 
4 
46,XX.t(4;11;14)(q13;q23;q32)[161/46,XX[31  R  -  ND  2 
8  Inadequate study  R  ND  37+ 
10 
1 
46,XX,der~~~t(?l;~~~?q21;q21),de1~7~~p13~,der~ll~t(~;ll)(q21;q23)  R  +  MLL6/AF-4b  2 
121/46,XX1181 
11  46,XX,t(4; 1  l)(q21;q23)I141/46,XX[61  R  +  MLL81AF-4aX  6 
12  46,XY,t~4;11~(q27;q23~[71146,XY,t~4;ll~~q2l;q23~t~l4;l8~~q3Z;qll.2~  R  +  MLL7IAF-4a  1 
171/46,XV[61 
13  46.XY.t(4;11)(q21;q23)121  R  +  MLL6/AF-4a  4 
14  46,XX,t(4;11)(q21;q23)[10]/46,XX[lOl  R  +  MLL6/AF-4aX  4 
15  46,XY.t(4;11)(q21;q23)131/46,XY[101  R  +  MLL6/AF-4aX  3 
Abbreviations: G, germline; R, rearranged; ND, not detected. 
* Sequence previously reported. 
were  taken  off  protocol for BMT in  first remission (Table 
3). One of  these patients (no. 32), who was treated with  an 
unrelated donor transplant 7 months after achieving remis- 
sion, remains disease-free 38 months after BMT. The other 
patient (no.  1 l), who was treated with  an  allogeneic BMT 
2.5 months after achieving remission, has relapsed and died. 
The results of salvage therapy in those infants with  MLL 
gene rearrangement who have relapsed are shown for those 
that received BMT (Table 3)  and  chemotherapy (Table 4). 
The median survival after relapse for babies salvaged with 
chemotherapy was  140 days;  1 of  the  12 children treated 
remains alive  without  disease. For  those receiving  trans- 
plants in second or later remission, the median survival after 
relapse was 310 days; 2 of  8 are alive and disease-free 13 
and  14 months, respectively, from relapse. The cause  of 
death in  both  groups was relapsed disease in all but  1 case. 
MRD analysis.  RT-PCR for detection of  MLLIAF-4 fu- 
sion  transcripts was  undertaken in  4  patients  at different 
timepoints on therapy (Fig 2). Dilutions of  RNA  from the 
RS(4; 11) cell line in  RNA from the non-t(4; 11) cell line 
Table 2.  Details of  Infants  Studied  for  MLL Gene  Rearranaement 
MLL Rearranged  MLL  Germline 
Total no.  29  11 
CDlO-  26  2 
CD19'  25 (3  ND)  8 (2  ND) 
Median WBC (range)  225  (5-2.810)  24  (2-90) 
Median age in mo  (range)  5 (1-11)  10 (4-11) 
No. achieving remission by day 28  27  11 
No. relapsing  22  1 
Cytogenetics 
1 lq23 abnormality  19  0 
Other abnormalities  1  3 
Insufficient or NA  7  2 
Normal  2  6 
Nalm-6 were tested. This method detects message from  1 
cell in  IO',  which is comparable to other PCR  assays for 
minimal disease.'9~20~27~2s  Note that  more  than  one size tran- 
script may  be  detected, resulting from alternative splicing, 
as previously reported." 
Patient A,  an  infant, was studied in  first  remission at  1.5 
years into maintenance therapy. No t(4; 11) transcripts were 
detected in testing this single marrow specimen in duplicate. 
Patient B is  14 years old and  was  treated with  unrelated 
donor  BMT  after consolidation (preparative regimen Cy- 
toxadtotal body irradiation [TBI]). We detected transcripts 
in the diagnostic blasts (PB l),  in the PB and BM after consol- 
idation (PB2 and BM2), and in the postmortem specimens 
from spleen (Sp13) and  BM  (BM3), all  in morphologic remis- 
sion. Blood (PB3) on the last day of life (the patient died 6 
months post-BMT from infection) was negative. 
Patient  C,  an  infant,  was  treated  with  unrelated donor 
BMT (prepared with CytoxanfTBI) during maintenance; he 
died 4 months after transplantation of  interstitial pneumoni- 
tis. Transcripts were detected pre-BMT (BMI) and in (mor- 
phologic remission) marrows at day  100 (BM2), day  125 
(BM3), and day  157 (BM4) post-BMT. Blood on the last 
day of  life (PB4) was negative. Patient D, who was 20 years 
of age, received an unrelated donor BMT after consolidation 
(prepared with  VP-16,  cytoxan, TBI, and B43-PAP [anti- 
CD191  immunotoxin)."  He died from infection 6 months 
after transplantation. Transcripts were detected at diagnosis 
(BMl) and after consolidation (BM2, BM3, and BM4, all 
remission marrows), but were not detected 21 (BM3 or 52 
(BM6) days after transplantation or in the postmorten spleen, 
liver, or marrow (BM7). All specimens were positive when 
tested for @-actin,  indicating the isolation of  intact RNA. 
DISCUSSION 
Treatment of leukemia has been improved by the identifi- 
cation of prognostic markers. The anticipated application of 
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Fig 1.  EFS curves in infant ALL with and  without 
MLL gene rearrangement. 
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molecular markers in the assignment of  treatment groups 
must  be performed with  concurrent comparison to  estab- 
lished parameters such as cytogenetics and immunopheno- 
typing.  In  infant  ALL,  cytogenetic  data  show  that  the 
t(4; 1  l)(q21;q23)  translocation  portends  a  poor  progno- 
s~s.'*'~*'~  Several groups have shown that MLL (1 lq23) gene 
rearrangement, as detected by Southern blot, carries a poor 
prognosis in infant  The purpose of this study was 
to simultaneously evaluate cytogenetics, Southern analysis 
of  MLL gene rearrangment, and  RT-PCR  for detection of 
the MLUAF-4 fusion transcript in infant ALL in the context 
of outcome. With other investigators reporting intermediate 
survival  (from  50%  reported  by  the  Pediatric  Oncology 
Group"  to the 67% reported by  Cimino et all2) in infants 
with germline MLL configuration, in contrast to the 80% 
survival seen in infants treated on CCG protocols, we also 
sought to add to and update the survival curve for the CCG 
infants studied for MLL status. 
The results show, as expected, that molecular techniques 
detect rearrangement of the MLL and  AF-4 genes not found 
by  cytogenetics and that PCR at this point cannot replace 
Southern blotting for MLL gene status. They also underscore 
the continued need for cytogenetic testing. Patients no. 6,7, 
and 9 illustrate the questions clinicians will consider to make 
therapeutic decisions based on these tests. In patients no.  6 
and 7 (rearranged at MLL), cytogenetics show t(4; 11) with 
nonclassic breakpoints, and, as anticipated, PCR does not 
detect a classic MLIJAF-4 fusion transcript. In patient no. 
9, there were insufficient metaphases for analysis, but RT- 
PCR  identified a t(4; 11) fusion transcript. We must decide 
how  a  recommendation for BMT for t(4; 11) leukemia in 
first remission would apply to these patients. 
RT-PCR for t(4; 11) is difficult because the AF-4 gene 
remains largely uncharacterized, and a particular set of prim- 
ers may  miss uncommon AF-4  translocation breakpoints. 
Several groups have cloned and sequenced most  of the AF- 
Table 3.  BMT in infant MLL-Rearranged  ALL 
BMT  Survival (mo) 
Patient 
No. 
Donor 
32  URD  CR  1  CyrrBl  NA  38+  NA  NA  t(4;11)(q21;q23) 
Type 
Duration  From  From  Cause  1 lq23 Cytogenetic 
Timing  Prep  CR1 (mob  BMT  Relapse  of Death  Abnormality 
11  MSD  CR  1  CyrrBl  NA  2  NA  PD  t(4;11)(q21;q23) 
7  Haplo  CR2  BuICylAra-CnBI  13  3  3  LPD  t(4;11)(q35;q14-22) 
23  Haplo  CR2  CyFBl  4  5  7  PD  t(4;11)(q21;q23) 
15  URD  CR2  BulCylAra-CFBI  3  5  5  PD  t(4;11)(q21;q23) 
13  MSD  CR2  BuICYNP-16  4  12+  13+  NA  t(4;11)(q21;q23) 
5  URD  CR2  Ara-CFBI  4  9+  14+  NA  Not available 
12  Auto  CR2  BUICY  1  8  10  PD  t(4;11)(q21;q23) 
14  URD  CR2  Ara-CFBI  4  9  11  PD  t(4;11)(q21;q23) 
21  Auto  CR3  CYFBI  9  3  5  PD  Inadequate study 
Abbreviations:  NA,  not applicable; LPD,  lymphoproliferative disease;  PD,  progressive disease;  Haplo,  haploidentical family  donor;  MSD, 
matched sibling donor; URD, unrelated donor; Auto,  autologous donor; CR.  complete remission. 
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Table 4.  Chemotherapy'as  Salvage  Therapy  in Infant  MLL-Rearranged  ALL 
Patient No.  llq23  Chemotherapy  Duration  CR1 (mol  Survival (mo) From Relapse  Cause of Death  Cytogenetic Abnormality 
6  v,  p.  L.  c  2  4  Sepsis  t(4;11;14)(q13;q23;q32) 
18  V.  P,  L.  D.  A.  T.  M  8  4  PD  t(4;ll)(q21;q23) 
19  V.  P.  L.  D,  A.  T.  M  35  50 +  NA  t(4;11)(q21;q23) 
22  C,L,P,D,A,TG,B,Ca  11  7  PD  Not  done 
24  V,  P,  L,  M,  A,  H, Ida  7  1  PD  t(4;1l)(q21;q23) 
25  V,  P,  L, D,  TG,  A,  E  11  4  PD  t(4;11)(q21;q23) 
26  V.  P.  L.  D,  A. T.  M  6  21  PD  t(4;11)(q21;q23) 
9  V.  P.  L.  D.  A.  M  1  4  PD  Inadequate  study 
28  V,  P.  L.  D  3  5  PD  t(4;11)(q21;q23) 
29  V,P,L,D,A,E,Az,IT  7  10  PD  t(4;11)(q21;q23) 
10  V,  P,  M.  1,  E  2  2  PD  der(ll)t(4;11)(q21;q23) 
20  V.  P.  L. D.  A.  T.  M  5  5  PD  t(4;11)(q21;q23) 
27  None  given  3  4  PD  t(4;ll)(q21;q23) 
Abbreviations: A,  Ara-C; Az,  5-azacytidine; B.  BCNU; Ca.  carboplatin; C,  cytoxan; D,  Daunomycin; E,  etoposide;  Ida, idarubicin; I, ifosfamide; 
IT,  intrathecal  triple  therapy;  H, hydrocortisone; L,  L-asparaginase;  M,  IV  methotrexate;  P,  prednisone;  T,  teniposide;  TG,  6-thioguanine;  V, 
vincristine; ND,  not done;  NA, not applicable; PD.  progressive  disease 
4/FEL gene.'"-3'  Limited  work  has been  performed at the 
genomic level: however, breakpoints in AF-4 are distributed 
over 38 kb,32  which  is  a large genomic area compared with 
the breakpoint clustering seen in the MLL  55 MLU 
AF-4 fusion transcripts have  been  reported so far by several 
investigators; all have shown the fusion of  MLL to one of 
three AF-4 ex on^.^"'^^^^  The RT-PCR primers used  in this 
study encompass this area and an area 400 bp downstream 
as  well. Nonetheless, RT-PCR primers designed based  on 
these data may  miss  a rare breakpoint elsewhere in the AF- 
4 gene or one involving a different gene on chromosome 4. 
Thus, treatment decisions based  on  this test alone must be 
carefully  considered,  and  Southern  blot  for  MLL  re- 
arrangement remains the important test detecting poor-prog- 
nosis patients. 
MLL gene rearrangement is clearly associated with age 
less than 6 months and hyperleukocytosis, and it portends a 
poor prognosis in infants."."  However, it remains unclear 
whether infants with germline MLL are a group with a good 
prognosis. Chen et al'' reported an  80% EFS at 4 years for 
infants with germline MLL treated on CCG protocols; others 
report  an  EFS  as  low  as  50% for  infants  with  germline 
MLL." Because of  this discrepancy, we  have updated  and 
extended the results for the  CCG  infants and report that our 
germline group continues to do extremely well, with only  1 
relapse among  11 infants. Different groups may  be  seeing 
other  high-risk translocations among their infants without 
MLL rearrangement; there were  no  such translocations in 
our germline infants. Because therapy  is  intensified  for in- 
fants  with  ALL,  those without  MLL gene  rearrangement 
should be excluded from more toxic therapy. 
Our group of  infants with MLL gene rearrangement has 
done poorly even with  more  aggressive management; 16 of 
the 29 infants were treated  on the recently completed proto- 
col  1883 consisting of aggressive cytoreductive therapy ad- 
ministered immediately after induction and again with a rein- 
tensification. They continue to relapse early. In  collecting 
follow-up data on these infants, we ascertained the salvage 
therapy used  for relapsed patients. Table 3  shows the out- 
come for those infants salvaged with BMT (and also shows 
2  treated  in  first  remission). Table 4 shows outcomes for 
patients treated  with  chemotherapy. Two patients receiving 
transplants in CR2 remain disease-free  13  and  14  months, 
respectively, after relapse; the others died of subsequent re- 
lapsed disease (5/6)  or of lymphoproliferative disease (l/6). 
The  median  postrelapse survival was  310 days  for those 
receiving transplants. Of  those treated  with  chemotherapy, 
1 patient still survives 50 months from relapse. The median 
postrelapse survival was  140 days, and  all  but  1  died  of 
progressive disease. 
Pt. c  .  Pt. D 
530 - 
410- 
230 - 
Fig 2.  Detection  of  MLLIAF-4  fusion  transcripts  in patients  on  therapy.  (A)  t(4;ll)  RT-PCR products  after  Southern  blotting.  (B) p-actin PCR 
products,  ethidium  bromide  staining.  Spl, spleen;  Liv, liver.  The  timing  of  each  specimen  relative  to  therapy  is  described  in the text. 
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Resistant disease, and  not toxicity of therapy,  remains the 
problem  for  both  forms  of salvage therapy. This  raises  the 
question of timing of BMT. Of 2 patients  receiving  trans- 
plants  in  first  remission  (Table  3), 1 patient  had  a  relapse 
within 2 months  (BMT 2.5 months  after  achieving  CR)  and 
1 patient who  received an  unrelated  donor  BMT  (8 months 
after  CR)  remains  free  of disease 38 months  after  BMT  and 
47 months  from  diagnosis. 
The  preliminary  results we present  here of the  assessment 
of minimal disease in t(4;  11) leukemia  are  from a  small  but 
intriguing  group  of patients.  Residual  disease  was  detected  in 
some patients  in  morphologic  remission  even after intensive 
therapy  including  BMT.  These  findings  will be  pursued  in 
further studies of minimal disease  using  quantitative  tech- 
niques  in  infants  on  therapy. 
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